Omeros Story Continues to Get Better, but Reimbursement Risk Remains


The fundamentals behind Omeros’ (NASDAQ:OMER) eye drug Omidria continue to get better, but Cantor analyst Elemer Piros believes the company still needs to remove the uncertainty around the expiration of pass-through reimbursement.

Story Continues